Amber Awa van der Heijden

Amber Awa van der Heijden

Auto-generated profile, based on publicly available information

Amber Awa van der Heijden

Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2017 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
AHAmber A Van Der Heijden
Amber A Van Der Heijden
MAMichael D Abramoff
Michael D Abramoff
FVFrank Verbraak
Frank Verbraak
MHManon V Van Hecke
Manon V Van Hecke
ALAlbert Liem
Albert Liem
GNGiel Nijpels
Giel Nijpels
Purpose: To increase the efficiency of retinal image grading, algorithms for automated grading have been developed, such as the IDx‐DR 2.0 device. We aimed to determine the ability of this device, incorporated in clinical work flow, to detect retinopathy in persons with type 2 diabetes.Methods: Retinal images of persons treated by the Hoorn Diabetes Care System (DCS) were graded by the IDx‐DR device and independently by three retinal specialists using the International Clinical Diabetic Retinopathy severity scale (ICDR) and EURODIAB criteria. Agreement between specialists was calculated. Results of the IDx‐DR device and experts were compared using sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), distinguishing between referable diabetic retinopathy (RDR) and vision‐threatening retinopathy (VTDR). Area under the receiver operating characteristic curve (AUC) was calculated.Results: Of the included 1415 persons, 898 (63.5%) had images of sufficient quality according to the experts and the IDx‐DR device. Referable diabetic retinopathy (RDR) was diagnosed in 22 persons (2.4%) using EURODIAB and 73 persons (8.1%) using ICDR classification. Specific intergrader agreement ranged from 40% to 61%. Sensitivity, specificity, PPV and NPV of IDx‐DR to detect RDR were 91% (95% CI: 0.69–0.98), 84% (95% CI: 0.81–0.86), 12% (95% CI: 0.08–0.18) and 100% (95% CI: 0.99–1.00; EURODIAB) and 68% (95% CI: 0.56–0.79), 86% (95% CI: 0.84–0.88), 30% (95% CI: 0.24–0.38) and 97% (95% CI: 0.95–0.98; ICDR). The AUC was 0.94 (95% CI: 0.88–1.00; EURODIAB) and 0.87 (95% CI: 0.83–0.92; ICDR). For detection of VTDR, sensitivity was lower and specificity was higher compared to RDR. AUC's were comparable.Conclusion: Automated grading using the IDx‐DR device for RDR detection is a valid method and can be used in primary care, decreasing the demand on ophthalmologists.

1 October 2007 in Obesity
Verified
Journal Article
Closed access
PDF file
AHAmber A.W.A. van der Heijden
Amber A.W.A. van der Heijden
FHFrank B. Hu
Frank B. Hu
EREric B. Rimm
Eric B. Rimm
RDRob Van Dam
Rob Van Dam

1 November 2009 in Diabetes Care
Verified
Journal Article
Open access
AHAmber A.W.A. van der Heijden
Amber A.W.A. van der Heijden
MOMonica M. Ortegon
Monica M. Ortegon
LNLouis Niessen
Louis Niessen
GNGiel Nijpels
Giel Nijpels
JDJacqueline M. Dekker
Jacqueline M. Dekker
OBJECTIVE: To test the validity of the Framingham, Systematic Coronary Risk Evaluation (SCORE), and UK Prospective Diabetes Study (UKPDS) risk function in the prediction of risk of coronary heart disease (CHD) in populations with normal glucose tolerance (NGT), intermediate hyperglycemia, and type 2 diabetes. RESEARCH DESIGN AND METHODS: Calibration and discrimination of the three prediction models were tested using prospective data for 1,482 Caucasian men and women, 50–75 years of age, who participated in the Hoorn Study. All analyses were stratified by glucose status. RESULTS: During 10 years of follow-up, a total of 197 CHD events, of which 43 were fatal, were observed in this population, with the highest percentage of first CHD events in the diabetic group. The Framingham and UKPDS prediction models overestimated the risk of first CHD event in all glucose tolerance groups. Overall, the prediction models had a low to moderate discriminatory capacity. The SCORE risk function was the best predictor of fatal CHD events in the group with NGT (area under the receiver operating characteristic curve 0.79 [95% CI 0.70–0.87]), whereas the UKPDS performed better in the intermediate hyperglycemia group (0.84 [0.74–0.94]) in the estimation of fatal CHD risk. After exclusion of known diabetic patients, all prediction models had a higher discriminatory ability in the group with diabetes. CONCLUSIONS: The use of the Framingham function for prediction of the first CHD event is likely to overestimate an individual's absolute CHD risk. In CHD prevention, application of the SCORE and UKPDS functions might be useful in the absence of a more valid tool.

14 February 2019 in Diabetes Care
Verified
Journal Article
Open access
PDF file
FVFrank D. Verbraak
Frank D. Verbraak
MAMichael D. Abramoff
Michael D. Abramoff
GBGonny C.F. Bausch
Gonny C.F. Bausch
CKCaroline Klaver
Caroline Klaver
GNGiel Nijpels
Giel Nijpels
AHAmber A. van der Heijden
Amber A. van der Heijden
OBJECTIVE To determine the diagnostic accuracy in a real-world primary care setting of a deep learning–enhanced device for automated detection of diabetic retinopathy (DR). RESEARCH DESIGN AND METHODS Retinal images of people with type 2 diabetes visiting a primary care screening program were graded by a hybrid deep learning–enhanced device (IDx-DR-EU-2.1; IDx, Amsterdam, the Netherlands), and its classification of retinopathy (vision-threatening [vt]DR, more than mild [mtm]DR, and mild or more [mom]DR) was compared with a reference standard. This reference standard consisted of grading according to the International Clinical Classification of DR by the Rotterdam Study reading center. We determined the diagnostic accuracy of the hybrid deep learning–enhanced device (IDx-DR-EU-2.1) against the reference standard. RESULTS A total of 1,616 people with type 2 diabetes were imaged. The hybrid deep learning–enhanced device’s sensitivity/specificity against the reference standard was, respectively, for vtDR 100% (95% CI 77.1–100)/97.8% (95% CI 96.8–98.5) and for mtmDR 79.4% (95% CI 66.5–87.9)/93.8% (95% CI 92.1–94.9). CONCLUSIONS The hybrid deep learning–enhanced device had high diagnostic accuracy for the detection of both vtDR (although the number of vtDR cases was low) and mtmDR in a primary care setting against an independent reading center. This allows its’ safe use in a primary care setting.

1 May 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
AHAmber Awa van der Heijden
Amber Awa van der Heijden
SRSimone P Rauh
Simone P Rauh
JDJacqueline M Dekker
Jacqueline M Dekker
JBJoline W Beulens
Joline W Beulens
PEPetra Elders
Petra Elders
GNGiel Nijpels
Giel Nijpels
Purpose People with type 2 diabetes (T2D) have a doubled morbidity and mortality risk compared with persons with normal glucose tolerance. Despite treatment, clinical targets for cardiovascular risk factors are not achieved. The Hoorn Diabetes Care System cohort (DCS) is a prospective cohort representing a comprehensive dataset on the natural course of T2D, with repeated clinical measures and outcomes. In this paper, we describe the design of the DCS cohort. Participants The DCS consists of persons with T2D in primary care from the West-Friesland region of the Netherlands. Enrolment in the cohort started in 1998 and this prospective dynamic cohort currently holds 12 673 persons with T2D. Findings to date Clinical measures are collected annually, with a high internal validity due to the centrally organised standardised examinations. Microvascular complications are assessed by measuring kidney function, and screening feet and eyes. Information on cardiovascular disease is obtained by 1) self-report, 2) electrocardiography and 3) electronic patient records. In subgroups of the cohort, biobanking and additional measurements were performed to obtain information on, for example, lifestyle, depression and genomics. Finally, the DCS cohort is linked to national cancer and all-cause mortality registers. A selection of published findings from the DCS includes identification of subgroups with distinct development of haemoglobin A1c, blood pressure and retinopathy, and their predictors; validation of a prediction model for personalised retinopathy screening; the assessment of the role of genetics in development and treatment of T2D, providing options for personalised medicine. Future plans We will continue with the inclusion of persons with newly diagnosed T2D, follow-up of persons in the cohort and linkage to morbidity and mortality registries. Currently, we are involved in (inter)national projects on, among others, biomarkers and prediction models for T2D and complications and we are interested in collaborations with external researchers. Trial registration ISRCTN26257579

25 January 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
BCBIOS consortium
BIOS consortium
SYSoheil Yousefi
Soheil Yousefi
TATooba Abbassi-Daloii
Tooba Abbassi-Daloii
TKThirsa Kraaijenbrink
Thirsa Kraaijenbrink
MVMartijn Vermaat
Martijn Vermaat
PHPeter A. C. ’t Hoen
Peter A. C. ’t Hoen
SNP panels that uniquely identify an individual are useful for genetic and forensic research. Previously recommended SNP panels are based on DNA profiles and mostly contain intragenic SNPs. With the increasing interest in RNA expression profiles, we aimed for establishing a SNP panel for both DNA and RNA-based genotyping. To determine a small set of SNPs with maximally discriminative power, genotype calls were obtained from DNA and blood-derived RNA sequencing data belonging to healthy, geographically dispersed, Dutch individuals. SNPs were selected based on different criteria like genotype call rate, minor allele frequency, Hardy–Weinberg equilibrium and linkage disequilibrium. A panel of 50 SNPs was sufficient to identify an individual uniquely: the probability of identity was 6.9 × 10− 20 when assuming no family relations and 1.2 × 10− 10 when accounting for the presence of full sibs. The ability of the SNP panel to uniquely identify individuals on DNA and RNA level was validated in an independent population dataset. The panel is applicable to individuals from European descent, with slightly lower power in non-Europeans. Whereas most of the genes containing the 50 SNPs are expressed in various tissues, our SNP panel needs optimization for other tissues than blood. This first DNA/RNA SNP panel will be useful to identify sample mix-ups in biomedical research and for assigning DNA and RNA stains in crime scenes to unique individuals.